Insider Cluster (4 insiders) ·Filed Mar 2, 2026

QURE

uniQure N.V.
NEUTRAL
Impact 4/10
Horizondays Processed6mo ago
Insider cluster: 4 insiders, $0.6M total
Actionable Insight • Neutral

Monitor for follow-up selling in coming weeks; if open-market dispositions continue beyond this cluster, it could signal weakening confidence. Otherwise, this appears to be a routine post-grant transaction.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
QURE ▲ +139.52% at T+60d
NEUTRAL call ✓ call won +139.52% · α vs SPY +130.20% · entry $10.50 → $25.15
Entry anchored
Feb 27, 03:59 PM ET
via exchange tick
T+1d
-14.00%
call -14.00% · α -13.09%
$9.03
settled 7mo ago
T+5d
+71.33%
call +71.33% · α +72.54%
$17.99
settled 7mo ago
T+20d
+40.29%
call +40.29% · α +48.22%
$14.73
settled 6mo ago
T+60d
+139.52%
call +139.52% · α +130.20%
$25.15
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

uniQure's top executives, including the CEO, CFO, CMO, and Chief Legal Officer, were granted stock awards totaling over 187,000 shares (non-cash) while simultaneously selling nearly $570,000 worth of shares in the open market. The sales represent approximately 0.085% of the company's $666M market cap and appear to be routine portfolio management following a grant vesting event.

Key Financial Metrics

Direction
selling
Total Value
$569.2K
Insiders
4

Key Facts

  • CEO Kapusta sold $342,648 in shares; CFO Klemt sold $124,693; CMO Abi-Saab sold $16,517; Chief Legal Officer Potts sold $85,351
  • All four executives received new share grants totaling 187,300 shares at $0 (non-cash awards)
  • Total open-market sales: $569,209 across 57,207 shares at $9.95 per share
  • Sales amount to ~0.085% of $666M market cap — below the 0.1% threshold for materiality
  • Transaction pattern (sell after grant) is common in biotech and often relates to tax planning or diversification

Financial Impact

$569,209 in net insider selling, offset by non-cash grants

insider ownershipshare count (dilution from grants)

Risk Factors

  • Perception of insider selling despite non-cash grants may weigh on sentiment
  • Biotech executives often sell after vesting — pattern should be watched for escalation

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (8 trades, 7d window)cluster-QURE-1772834899834
32 reports for QURE
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +27.15%Jul 29, 2026
Filters
Rows
Reports for QURE — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BULLISH ★ 7/10
$46.23 $44.47▼ −3.81%▼ −2.85%$23.46 (−49.25%)
Jul 29, 2026
9w ago
8-K
BULLISH ★ 8/10
$40.07 $44.24▲ +10.41%▲ +4.88%$23.46 (−41.45%)
Jul 7, 2026
12w ago
Insider Cluster
BEARISH ★ 5/10
$41.41 $41.52▼ −0.27%▲ +0.29%$23.46 (+43.35%)
Jul 2, 2026
13w ago
Insider Cluster
BEARISH ★ 4/10
$41.81 $44.48▼ −6.39%▼ −5.46%$23.46 (+43.89%)
Jul 2, 2026
13w ago
Insider Cluster
MIXED ★ 5/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jul 2, 2026
13w ago
144
NEUTRAL ★ 2/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 2/10
$45.17 $41.41▼ −8.32%▼ −8.59%$23.46 (−48.06%)
Jun 25, 2026
14w ago
144
BEARISH ★ 5/10
$47.51 $41.81▲ +12.00%▲ +14.16%$23.46 (+50.62%)
Jun 24, 2026
14w ago
424B5
MIXED ★ 6/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 6, 2026